We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
- Authors
Brunnberg, U; Mohr, M; Noppeney, R; Dürk, H A; Sauerland, M C; Müller-Tidow, C; Krug, U; Koschmieder, S; Kessler, T; Mesters, R M; Schulz, C; Kosch, M; Büchner, T; Ehninger, G; Dührsen, U; Serve, H; Berdel, W E
- Abstract
Chemotherapy for elderly patients with acute myeloid leukemia (AML) results in a median overall survival (OS) of ≤ 1 year. Elderly patients often present with cardiac comorbidity. Gemtuzumab ozogamicin (GO) is active in elderly (≥ 60 years) patients with relapsed AML with low cardiac toxicity.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 4, p990
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdr346